Oramed Pharm pivots with Lifeward strategic platform deal

The latest update is out from Oramed Pharm ( (ORMP) ).

On January 12, 2026, Oramed Pharmaceuticals entered into a set of strategic agreements with Lifeward Ltd. under which Oramed will transfer its POD™ oral drug delivery platform, including its investigational oral insulin capsule, to Lifeward in exchange for Lifeward shares, pre-funded warrants, additional share purchase warrants and a 4% royalty on net revenue from Lifeward’s ReWalk personal exoskeleton franchise for up to 10 years or until other specified conditions are met. The structure of the deal, which remains subject to customary closing conditions and shareholder approvals, will make Oramed a significant shareholder with up to 49.9% beneficial ownership of Lifeward and gives it the ability to further increase its stake through senior secured convertible notes and associated warrants totaling up to $20 million in principal, most of which Oramed has agreed to purchase. Oramed will continue to manage the clinical trial program for the oral insulin candidate under a clinical trial management agreement, while Lifeward, a revenue-generating medical robotics company whose FDA-approved ReWalk and AlterG systems produced $26 million in sales over the last four reported quarters, will integrate the POD™ platform into its portfolio. The transaction effectively pivots Oramed from a pure-play oral drug delivery developer into a major strategic and financial stakeholder in a diversified medical robotics and drug-delivery business, while potentially providing Lifeward with both a new growth avenue in diabetes and additional capital aimed at driving the ReWalk and AlterG lines toward profitability.

The most recent analyst rating on (ORMP) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Oramed Pharm stock, see the ORMP Stock Forecast page.

Spark’s Take on ORMP Stock

According to Spark, TipRanks’ AI Analyst, ORMP is a Neutral.

The score is held back mainly by weak operating fundamentals and persistent cash burn despite a strong, low-debt balance sheet. Offsetting that, technicals are in an uptrend, valuation looks inexpensive on P/E, and corporate events (liquidity gains and a cash dividend) are supportive.

To see Spark’s full report on ORMP stock, click here.

More about Oramed Pharm

Oramed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company and platform-technology specialist focused on oral delivery solutions for drugs currently administered by injection. Its proprietary Protein Oral Delivery (POD™) technology is designed to protect biologic drug integrity and enhance absorption, with a key focus on an oral insulin program, while the company also builds a diversified portfolio of strategic healthcare investments.

Average Trading Volume: 197,399

Technical Sentiment Signal: Hold

Current Market Cap: $136.5M

Learn more about ORMP stock on TipRanks’ Stock Analysis page.